Human Genome Sciences faces FDA regulatory delay on anthrax treatment
Human Genome sees FDA delay with anthrax treatment Alkermes says its anti-alcoholism drug met goal in late stage trial against opioid addiction
Alkermes’ Vivitrol succeeds in opiate study Niacin shrinks artery plaque; Merck’s Zetia does not and may carry risks, new study finds
Study raises new questions about Merck pill Zetia |